The aims of our participation in the Children's Cancer Group are: 1. To continue our excellent record of patient accrual and data acquisition for therapeutic and biologic studies. 2. To continue to expand our scientific leadership role in our areas of greatest strength, including molecular biology, neuroblastoma, brain tumors, myelodysplasia and high-risk leukemias, supportive care, germ cell tumors, hepatoblastomas, and lymphomas. 3. Pilot new innovative therapeutic studies for the CCG, particularly in brain tumors, neuroblastoma, and bone marrow transplantation. Patient accrual from UCSF and affiliates has continued to increase in the past five years, and we are one of the leading contributors to group biology and therapeutic studies. Our scientific leadership is shown by membership on 6 disease strategy groups, and members of our group are chair or co-chair of 5 discipline and strategy committees and 21 study protocols. Overall, we hold 138 appointments on CCG committees. We are conducting important pilot studies for the group, including dose- intensive continuous infusion chemotherapy for neuroblastoma, which with and without autologous bone marrow infusions, and multiple brain tumor pilots, including interferon with hyperfractionated radiation, radiosensitizers, and chemotherapy studies. A new biology study in myelodysplasia is proposed by two of our members and we have provided complete supportive care guidelines for the Group and continue to contribute in this area. Our strong biology research laboratories in brain tumors, neuroblastoma and myeloproliferative disorders are conducting multiple biology studies in the Group and providing new information for future studies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Smith, Malcolm M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Schools of Medicine
San Francisco
United States
Zip Code
Baker, David L; Schmidt, Mary L; Cohn, Susan L et al. (2010) Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 363:1313-23
Neudorf, Steven; Sanders, Jean; Kobrinsky, Nathan et al. (2004) Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood 103:3655-61
Seitzman, Robin L; Glover, Dorie A; Meadows, Anna T et al. (2004) Self-concept in adult survivors of childhood acute lymphoblastic leukemia: a cooperative Children's Cancer Group and National Institutes of Health study. Pediatr Blood Cancer 42:230-40
Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8
Casillas, Jacqueline N; Woods, William G; Hunger, Stephen P et al. (2003) Prognostic implications of t(10;11) translocations in childhood acute myelogenous leukemia: a report from the Children's Cancer Group. J Pediatr Hematol Oncol 25:594-600
Davies, Stella M; Bhatia, Smita; Ross, Julie A et al. (2002) Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 100:67-71
Wells, Robert J; Reid, Joel M; Ames, Matthew M et al. (2002) Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. J Pediatr Hematol Oncol 24:89-93
Lange, Beverly J; Bostrom, Bruce C; Cherlow, Joel M et al. (2002) Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99:825-33
Ou, Shu Xiao; Han, Dehui; Severson, Richard K et al. (2002) Birth characteristics, maternal reproductive history, hormone use during pregnancy, and risk of childhood acute lymphocytic leukemia by immunophenotype (United States). Cancer Causes Control 13:15-25
Cairo, M S; Krailo, M D; Morse, M et al. (2002) Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report. Leukemia 16:594-600

Showing the most recent 10 out of 117 publications